Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I

摘要

The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

主权项

1. A method of inhibiting IGF-1 actions in a subject in need of treatment for retinopathy, comprising administering to the subject an effective amount of an antibody that: (a) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a human β3 integrin, wherein said amino acids consist of SEQ ID NO:82; (b) does not specifically bind to the RGD binding site of a human β3 integrin or utilize the RGD binding site of human β3 integrin; and (c) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a pig β3 integrin, wherein said amino acids consist of SEQ ID NO:82, thereby inhibiting IGF-1 actions in the subject and treating the retinopathy in the subject.